NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
35.44
-0.30 (-0.84%)
At close: May 22, 2026, 4:00 PM EDT
36.60
+1.16 (3.27%)
After-hours: May 22, 2026, 4:58 PM EDT
NewAmsterdam Pharma Company Employees
NewAmsterdam Pharma Company had 100 employees as of December 31, 2025. The number of employees increased by 32 or 47.06% compared to the previous year.
Employees
100
Change
32
Growth
47.06%
Revenue / Employee
$225,650
Profits / Employee
-$2,127,330
Market Cap
4.14B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 100 | 32 | 47.06% |
| Mar 31, 2025 | 77 | 37 | 92.50% |
| Dec 31, 2024 | 68 | 39 | 134.48% |
| Sep 30, 2024 | 62 | 40 | 181.82% |
| Jun 30, 2024 | 57 | 35 | 159.09% |
| Mar 31, 2024 | 40 | 23 | 135.29% |
| Dec 31, 2023 | 29 | 12 | 70.59% |
| Jun 30, 2023 | 22 | - | - |
| Dec 31, 2022 | 17 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| ACADIA Pharmaceuticals | 798 |
| Crinetics Pharmaceuticals | 594 |
| Travere Therapeutics | 497 |
| CRISPR Therapeutics AG | 393 |
| Catalyst Pharmaceuticals | 182 |
| Dianthus Therapeutics | 92 |
| Oruka Therapeutics | 68 |
NAMS News
- 4 days ago - NewAmsterdam Pharma Company Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 12 days ago - NewAmsterdam Pharma Company Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 13 days ago - NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May - GlobeNewsWire
- 16 days ago - NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends - MarketBeat
- 18 days ago - NewAmsterdam Pharma Company Transcript: Investor update - Transcripts
- 18 days ago - NewAmsterdam Pharma Company Slides: Investor update - Filings
- 18 days ago - NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - GlobeNewsWire
- 18 days ago - NewAmsterdam Pharma Company Quarterly report: Q1 2026 - Filings